SAN DIEGO, CA, Feb. 15, 2022 (GLOBE NEWSWIRE) — via


NewMediaWire —






Medical Marijuana, Inc.


(OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today that its subsidiary


Kannaway®


achieved its largest revenue month in the company’s history in its Japan and South Africa divisions in January 2022.

According to Business Insider Africa, Africa’s cannabis industry is projected to grow beyond a


$7 billion valuation by 2023


. Reach and Markets highlights that the Asia-Pacific market is also expected to grow exponentially with a


CAGR of 28.6% from 2020 to 2027


.

“Being able to achieve four best revenue months in a row in the Japan market has been both a great way to end 2021 and an inspiring way to start 2022,” said Medical Marijuana, Inc. CEO Blake Schroeder. “Now that we’ve reached this milestone in South Africa as well, we anticipate that both regions will be major market areas for us this year and beyond.”

To learn more about Kannaway®, please visit the Company online at


https://www.kannaway.com/


.

About Kannaway®




Kannaway®


is a network sales and marketing company specializing in the sales and marketing of hemp-based botanical products. Kannaway® currently hosts weekly online sales meetings and conferences across the United States, offering unique insight and opportunity to sales professionals who are desirous of becoming successful leaders in the sale and marketing of hemp-based botanical products.

About Medical Marijuana, Inc.




We are a company of firsts®


. Medical Marijuana, Inc. (


MJNA


) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by


Kannaway®


and


HempMeds®


; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including


AXIM® Biotechnologies, Inc




.


and


Neuropathix


. Medical Marijuana, Inc. was named a top CBD producer by


CNBC


. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product


Real Scientific Hemp Oil


has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.

Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at


OTCMarkets.com


or by visiting


www.medicalmarijuanainc.com


. To see Medical Marijuana, Inc.’s corporate video,


click here


.

FORWARD-LOOKING DISCLAIMER


This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE


These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

LEGAL DISCLOSURE


Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

CONTACT:

Public Relations Contact:

Kathryn Brown

Account Director

CMW Media

P. 858-264-6600

[email protected]

www.cmwmedia.com

Investor Relations Contact:

P. (858) 283-4016

[email protected]